Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: High-frequency episodic migraine (HFEM) has gained attention in the field of headache research and clinical practice. In this narrative review, we analyzed the available literature to assess the evidence that could help decide whether HFEM may represent a distinct clinical and/or biological entity within the migraine spectrum.
Methods: The output of the literature search included 61 papers that were allocated to one of the following topics: (i) socio-demographic features and burden; (ii) clinical and therapeutic aspects; (iii) pathophysiology; and (iv) classification.
Results: Multiple features differentiate subjects with HFEM from low-frequency episodic migraine and from chronic migraine: education, employment rates, quality of life, disability and psychiatric comorbidities load. Some evidence also suggests that HFEM bears a specific profile of activation of cortical and spinal pain-related pathways, possibly related to maladaptive plasticity.
Conclusions: Subjects with HFEM bear a distinctive clinical and socio-demographic profile within the episodic migraine group, with a higher disease burden and an increased risk of transitioning to chronic migraine Recognizing HFEM as a distinct entity is an opportunity for the better understanding of migraine and the spectrum of frequency with which it can manifest, as well as for stimulating further research and more adequate public health approaches.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/03331024241291578 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Investigation of Sensory and Neuropsychological Parameters in Migraine Sufferers: A Cross-Sectional Study with Negative Findings.
Neurol Ther
September 2025
Department of Neurology, Neurocritical Care, and Neurorehabilitation, Christian Doppler University Hospital, Centre for Cognitive Neuroscience, Paracelsus Medical University, Member of ERN EpiCARE, 5020, Salzburg, Austria.
Introduction: Migraine headache not only is associated with high levels of suffering but also represents a considerable socioeconomic challenge. It is linked to various psychological and physiological impairments, including sensorimotor and somatosensory dysfunction, like those observed in other persistent pain syndromes. This study aims to determine whether individuals with high-frequency episodic (HFEM) or chronic migraine (CM) exhibit differences in somatosensory perception compared to healthy individuals and to explore potential correlations with neuropsychological features.
View Article and Find Full Text PDFNo Increase in Blood Pressure Assessed With the 24-h Holter Monitoring in Patients With Episodic Migraine During Early Treatment With Anti-CGRP Monoclonal Antibodies: A Prospective Observational Study (SAFHYPER).
Eur J Neurol
September 2025
Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Modena, Italy.
Background: Migraine is associated with an increased cardiovascular risk, including hypertension. Anti-calcitonin gene related peptide (CGRP) monoclonal antibodies (mAbs) are effective preventive treatments, but concerns have been raised about their potential hypertensive effects. Herein, we assess the early changes in blood pressure (BP) during anti-CGRP mAbs treatment in patients with migraine using 24-h Holter monitoring.
View Article and Find Full Text PDFExploring the Association of Migraine Susceptibility SNPs With the Risk of Chronic Migraine.
Eur J Pain
October 2025
Headache Science and Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia, Italy.
Background: Although robust genetic markers for episodic migraine (EM) have been identified, variants associated with chronic migraine (CM) are still unknown. Given the potential pathophysiologic overlap between EM and CM, we investigated whether six single nucleotide polymorphisms (SNPs), robustly associated with EM susceptibility (LRP1 rs11172113, PRDM16 rs10797381, FHL5 rs7775721, TRPM8 rs10166942, near TSPAN2 rs2078371 and MEF2D rs1925950) also play a role in the risk of developing CM.
Methods: A total of 200 EM and 202 CM participants were prospectively included.
Biofeedback therapy using Cerebri for the prevention of migraine attacks in adults with episodic migraine (BioCer): a randomized, wait-list controlled trial - the study protocol.
F1000Res
September 2025
Norwegian Centre for Headache Research (NorHead), Norwegian University of Science and Technology, Trondheim, Norway.
Introduction: Biofeedback is a non-pharmacological treatment option valued for its minimal risk of adverse events and offers a safe alternative for individuals seeking preventive care for migraine. Despite level A evidence for migraine prevention, biofeedback treatment is still unavailable to most patients. We developed a novel medical device (Cerebri) for multimodal biofeedback treatment that omits the need for healthcare personnel involvement.
View Article and Find Full Text PDFInteroception and dissociation in migraine: a case-control study of chronic and episodic subtypes.
Front Neurol
August 2025
Department of Clinical and Experimental Epilepsy, Institute of Neurology, University College London, London, United Kingdom.
Background: Migraine is one of the most common neurological disorders. Despite advances in understanding of episodic migraine, little is understood about the mechanisms underlying the chronification of migraine. Recently, increasing attention has been given to the potential roles of interoceptive abnormalities and dissociation.
View Article and Find Full Text PDF